How Do You Measure Success When It Comes to SLE?
EULAR 2021 opened with a grand debate to answer this essential question: should clinicians treat to remission or to Lupus Low Disease Activity State (LLDAS)?
News
Q-DAPSA for Measuring Disease Activity in PsA
Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.
RA ILD: Stepping out of the shadows
Despite being relatively common and frequently severe, RA-ILD has been a neglected area of research and indeed of clinical management in RA. In recent years we finally seem to have started making some progress in this area and this momentum has continued with a several interesting abstracts at EULAR 2021. Here are four selected for review.
EULAR 2021 Best Abstracts - Day 1
RheumNow faculty reporters scoured the Posters and Presentations from virtual EULAR 2021. Several of these are novel enough to be worthy of your consideration. Below is the list of the six most often retweeted abstracts from Day 1.
Lessons learned in SLE
An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351).
Combination vs. Sequential Therapy for the Treatment of Lupus Nephritis
Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal response.
Promising options to treat mucocutaneous disease in SLE
Cutaneous lupus erythematosus (CLE) consists of a wide range of dermatologic manifestations seen in people with or without systemic lupus erythematosus (SLE). CLE can be categorised into LE-specific lesions, i.e.
Can the Focus Score predict Lymphoma in Sjogren’s syndrome?
Patients with Sjogren’s syndrome are nearly 19 times more likely to develop lymphoma, so identifying factors that impact this risk development is a major goal in caring for this disorder.
EULAR 2021 - Day 3 Report
Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.
Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis
Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).
How do we personalize psoriatic arthritis treatment?
It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?
Israel provides COVID vaccine answers for rheumatic disease patients
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br
